In relation to clinical outcomes, Johnson and colleagues retrospectively analyzed 229 MM patients (60 NRAS-mutant, 53 BRAF-mutant and 116 wt/wt patients) that were treated with first-line immunotherapies, including interleukin-2, ipilimumab and anti-PD-1/PD-L1. This evidence concerns the gene NRAS and Miyoshi myopathy.